This study is for people with advanced HR+/HER2- breast cancer, a type of cancer that grows because of hormones but doesn't have too much of a protein called HER2. The study is testing new treatments: gedatolisib, which stops some cancer growth signals, and fulvestrant, which blocks hormones that fuel cancer. Some participants will also get palbociclib, a drug that slows cancer cell growth. The study checks how well these treatments work and how safe they are.
- Participation: You may be eligible if you have advanced breast cancer and have tried other treatments.
- Duration and Visits: Regular visits are required for assessments and treatment over several months.
- Risks and Benefits: Potential for side effects; discuss with your doctor if this trial is right for you.
Participants must not have certain health conditions like certain heart issues or uncontrolled diabetes. They also should not be pregnant or participating in other clinical trials. This study could help find better ways to treat this type of cancer. If you're interested, talk to your doctor to see if it's a good fit for you.